NovoCure Reports Increases in Active Patients on Optune Therapy

NovoCure Reports Increases in Active Patients on Optune Therapy

NovoCure, a commercial-stage oncology company developing a proprietary therapy for solid tumors, reported Tuesday preliminary operating statistics for Q4 and full year 2016, posting year-over-year increases in active patients on Optune therapy and prescriptions received. Optune is a novel therapy for newly diagnosed adult patients with glioblastoma. It is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area […]

Read More ˃
Global Payments Fiscal Q2 EPS and Sales Beat Estimates

Global Payments Fiscal Q2 EPS and Sales Beat Estimates

Global Payments reported adjusted earnings in Q2 fiscal 2017 surged 17% to $0.89 per share, beating the $0.84 average EPS estimate from analysts polled by Capital IQ. Sales over the three months that ended Nov. 30 soared to $941.8 million from $722.4 million a year ago, coming in above the $802.2-million consensus. In a release published early Monday, the company said it expects an adjusted EPS of $3.70 to $3.90 […]

Read More ˃
Stage Stores Plummets After Hours as Holiday Same-Store Sales Drop

Stage Stores Plummets After Hours as Holiday Same-Store Sales Drop

Stage Stores (SSI) shares tanked more than 24% after-hours on Friday as the company said holiday comparable sales fell 7.3% in the nine weeks ending Dec. 31. “Holiday comparable sales were below our expectations and increased promotions significantly pressured gross margin,” said Michael Glazer, president and chief executive officer. “Traffic remained weak with ongoing pressure in oil impacted and border states. However, we saw sequential sales improvement in the balance […]

Read More ˃
Sangamo BioSciences Changes Name to Sangamo Therapeutics

Sangamo BioSciences Changes Name to Sangamo Therapeutics

Sangamo Therapeutics said Friday that it has changed its corporate name from Sangamo Biosciences to Sangamo Therapeutics. The company’s common stock will continue to trade on the Nasdaq Global Select Market under the same ticker symbol “SGMO.” “Our new name, Sangamo Therapeutics, reflects our commitment to advance our groundbreaking science into the clinic for the development of transformative therapies for serious, genetically tractable diseases,” said CEO Sandy Macrae. The company […]

Read More ˃
European Equity Benchmarks Close Slightly Higher

European Equity Benchmarks Close Slightly Higher

The broad-based major European indices edged higher in Thursday’s trading session, as home builders, mining stocks, and automotive firms helped lift the markets. In economic news, industrial producer prices increased 0.3% in both the euro area (EA19) and the EU28 in November, compared with October, according to Eurostat, the statistical office of the European Union. In October, prices increased 0.8% in the euro area, and 1% in the EU28. In […]

Read More ˃